The withdrawal of mibefradil (Posicor)
Griffin
J P
JP
D001562:Benzimidazoles / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D004347:Drug Interactions; D004335:Drug and Narcotic Control; D006801:Humans; D020748:Mibefradil; D011358:Product Surveillance, Postmarketing; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*
D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil